{"id":"s-1-therapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-15%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL2105757","moleculeType":"Small molecule","molecularWeight":"289.29"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"S-1 is a prodrug that is converted into its active components, 5-fluorouracil (5-FU), 5-deoxy-5-fluoruridine (5-DFUR), and alanosine. These components then inhibit thymidylate synthase, which is essential for DNA synthesis and cell division. This leads to the death of rapidly dividing cancer cells.","oneSentence":"S-1 therapy is a chemotherapy medication that works by inhibiting thymidylate synthase, thereby preventing DNA synthesis and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:59.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07495501","phase":"","title":"Patient Satisfaction During Lomber Transforaminal Epidural Steroid Injection: The Role of Sedation, Anxiety, and Pain","status":"NOT_YET_RECRUITING","sponsor":"Mersin University","startDate":"2026-04-01","conditions":"Lumbar Disc Disease, Radiculopathy Lumbar, Radicular Pain","enrollment":120},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT04439318","phase":"PHASE2","title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-25","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":50},{"nctId":"NCT03041688","phase":"PHASE1","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-08","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":58},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07492615","phase":"PHASE2","title":"A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-29","conditions":"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":276},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07486674","phase":"NA","title":"Endoscopic and Cryoablation Denervation for Sacroiliac Joint Pain","status":"COMPLETED","sponsor":"EPC Education s.r.o.","startDate":"2023-04-20","conditions":"Sacroiliac Joint Pain, Chronic Pain","enrollment":51},{"nctId":"NCT07483567","phase":"PHASE2","title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-30","conditions":"CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07474324","phase":"PHASE2","title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-15","conditions":"GC/GEJC","enrollment":124},{"nctId":"NCT07467473","phase":"NA","title":"Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression","status":"ENROLLING_BY_INVITATION","sponsor":"Florida State University","startDate":"2026-03-23","conditions":"Left Rostromedial Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Dorsolateral Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Primary Somatosensory Cortex - Accelerated Intermittent Theta Burst","enrollment":48},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT05444439","phase":"NA","title":"Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-01-20","conditions":"H Pylori Infection","enrollment":100},{"nctId":"NCT07464756","phase":"PHASE2","title":"SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-04-05","conditions":"Gastric Adenocarcinoma","enrollment":80},{"nctId":"NCT03297281","phase":"NA","title":"Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","status":"RECRUITING","sponsor":"Clinique Pasteur","startDate":"2017-10-30","conditions":"Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction","enrollment":389},{"nctId":"NCT05933109","phase":"NA","title":"Mental Imagery and Targeted Memory Reactivation in PTSD","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2023-03-01","conditions":"Nightmares, REM-Sleep Type, PTSD","enrollment":46},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT04771520","phase":"PHASE2","title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-20","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":50},{"nctId":"NCT05878080","phase":"NA","title":"iTBS/fMRI Study of Hierarchical Control in the PFC","status":"COMPLETED","sponsor":"Florida State University","startDate":"2023-05-15","conditions":"Transcranial Magnetic Stimulation","enrollment":54},{"nctId":"NCT07222787","phase":"NA","title":"Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes (ILIF)","status":"ENROLLING_BY_INVITATION","sponsor":"Providence Medical Technology, Inc.","startDate":"2025-12-01","conditions":"Radiculopathy Lumbar, Degenerative Lumbar Disc Disease","enrollment":250},{"nctId":"NCT04244318","phase":"NA","title":"ODISEA Trauma: Parental Therapy Dispositive + Videofeedback 3.0","status":"COMPLETED","sponsor":"Esteban Gómez Muzzio","startDate":"2024-08-10","conditions":"Parent-Child Relations, Parenting, Parent-child Problem","enrollment":153},{"nctId":"NCT07225582","phase":"NA","title":"Development of Optimal Sensory Feedback Strategies to Maximize Function After Tetraplegia","status":"RECRUITING","sponsor":"Case Western Reserve University","startDate":"2026-01-13","conditions":"Spinal Cord Injury Cervical, Spinal Cord Injuries (Complete and Incomplete)","enrollment":3},{"nctId":"NCT07138040","phase":"NA","title":"Re-Engaging AYA Survivors in Cancer-Related Healthcare","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-08-01","conditions":"Cancer","enrollment":530},{"nctId":"NCT06519591","phase":"PHASE2","title":"Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-02-25","conditions":"Gastric Cancer Stage IV, Peritoneal Metastases","enrollment":40},{"nctId":"NCT05534321","phase":"PHASE1, PHASE2","title":"Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-08-29","conditions":"Spine Metastases","enrollment":74},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":"Advanced Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT07132762","phase":"NA","title":"The Effect of ESWT Added to Conservative Treatment on Pain, Disability, and Ultrasonographic Outcomes in Chronic Low Back Pain","status":"RECRUITING","sponsor":"Pamukkale University","startDate":"2025-10-10","conditions":"Chronic Low Back Pain","enrollment":44},{"nctId":"NCT06919172","phase":"NA","title":"iTBS/fMRI Study of Apex Control","status":"RECRUITING","sponsor":"Florida State University","startDate":"2025-01-06","conditions":"Transcranial Magnetic Stimulation","enrollment":40},{"nctId":"NCT07099755","phase":"NA","title":"This Study Aimed to Evaluate the Effect of Dynamic Neuromuscular Stabilization (DNS) on Pain Intensity and Functional Disability in Women With PLBP as Common Problem Affect t he Women After Birth Which Often Impacting Their Quality of Life and Ability to Perform Daily Activities","status":"COMPLETED","sponsor":"Gehad Alaa","startDate":"2025-08-01","conditions":"Post -Partum Low Back Pain, Dynamic Neuromuscular Stabilization (DNS), Women's Health / Physiotherapy","enrollment":60},{"nctId":"NCT06693128","phase":"PHASE2","title":"Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-21","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":80},{"nctId":"NCT07374250","phase":"PHASE2","title":"Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2026-02-01","conditions":"Gastric Cancer, RCT","enrollment":154},{"nctId":"NCT07214844","phase":"NA","title":"A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02","conditions":"Low Back Pain, Chronic","enrollment":110},{"nctId":"NCT07370233","phase":"PHASE2","title":"Triple Therapy Strategy for Managing Persistent Pain After Spinal Microdiscectomy","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-02-20","conditions":"Spinal Disk Injury","enrollment":63},{"nctId":"NCT07366528","phase":"PHASE3","title":"Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-15","conditions":"Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer","enrollment":387},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT04208347","phase":"PHASE2, PHASE3","title":"Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2019-12-18","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":580},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT07353684","phase":"PHASE2","title":"Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-05-11","conditions":"Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach","enrollment":49},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT07325630","phase":"PHASE2","title":"Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-03","conditions":"IBI363 + Chemotherapy","enrollment":60},{"nctId":"NCT07038629","phase":"PHASE2","title":"Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":52},{"nctId":"NCT07315854","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-11-04","conditions":"Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer","enrollment":32},{"nctId":"NCT07182565","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy","enrollment":84},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT03443492","phase":"PHASE2","title":"SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-03-26","conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":130},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":30},{"nctId":"NCT06576921","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-11-15","conditions":"Stomach Neoplasms, Immune Checkpoint Inhibitors","enrollment":116},{"nctId":"NCT07297914","phase":"PHASE2, PHASE3","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","status":"NOT_YET_RECRUITING","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2026-01-15","conditions":"Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease","enrollment":1000},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT06730009","phase":"PHASE1, PHASE2","title":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","status":"RECRUITING","sponsor":"Medigen Biotechnology Corporation","startDate":"2024-10-21","conditions":"Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable","enrollment":42},{"nctId":"NCT07285824","phase":"NA","title":"Virtual McKenzie Exercises and Centralization of Pain: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Evidence In Motion","startDate":"2025-12","conditions":"Chronic Pain, Low Back Pain","enrollment":40},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT03013010","phase":"PHASE3","title":"PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Shanghai Cancer Hospital, China","startDate":"2016-12","conditions":"Stomach Neoplasm, GastroEsophageal Cancer, Adenocarcinoma","enrollment":204},{"nctId":"NCT06584227","phase":"PHASE2","title":"Adebrelimab and Chidamide for Pancreatic Cancer","status":"RECRUITING","sponsor":"Liu Xiufeng","startDate":"2024-09-10","conditions":"Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT05322577","phase":"PHASE1, PHASE2","title":"A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-05-17","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":72},{"nctId":"NCT07263386","phase":"PHASE2","title":"A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-23","conditions":"Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07072351","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-15","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy","enrollment":88},{"nctId":"NCT07250256","phase":"NA","title":"Radiographic and Histomorphometric Evaluation of Xenograft as a Socket Preservation Material in Maxillary Posterior Teeth.","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2022-08-01","conditions":"Socket Preservation","enrollment":16},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT07246044","phase":"NA","title":"HD-tDCS for Adolescent Bipolar Depression Targeting S1","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-09-16","conditions":"Adolescent, Bipolar Depression, tDCS","enrollment":100},{"nctId":"NCT03449108","phase":"PHASE2","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-04-27","conditions":"Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone","enrollment":30},{"nctId":"NCT02892942","phase":"PHASE4","title":"NATural Ovarian Stimulation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-13","conditions":"Infertility","enrollment":129},{"nctId":"NCT05778474","phase":"","title":"Mechanical Determinants of Upper Limbs Oscillation During Gait","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2020-05-27","conditions":"Multiple Sclerosis, Poststroke/CVA Hemiparesis, Parkinson Disease","enrollment":25},{"nctId":"NCT06755593","phase":"NA","title":"Effectiveness of Intravascular Laser Therapy on Sleep Quality in Patients With Chronic Low Back Pain: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Le Hoang Minh Quan","startDate":"2024-04-01","conditions":"Sleep Disorders, Sciatica","enrollment":66},{"nctId":"NCT03107780","phase":"PHASE1","title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-09","conditions":"Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":32},{"nctId":"NCT01878617","phase":"PHASE2","title":"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-23","conditions":"Medulloblastoma","enrollment":660},{"nctId":"NCT07056361","phase":"NA","title":"Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control","status":"RECRUITING","sponsor":"Jorge Gonzalez-Martinez","startDate":"2022-12-16","conditions":"Movement Disorders (Incl Parkinsonism), Stroke, Traumatic Brain Injury","enrollment":60},{"nctId":"NCT05103527","phase":"NA","title":"Dorsal Root Ganglion Stimulation for the Treatment of Arthritic Knee Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kenneth B Chapman","startDate":"2022-01-01","conditions":"Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis","enrollment":30},{"nctId":"NCT06496867","phase":"NA","title":"Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2024-11-12","conditions":"Multiple Closed Pelvic Fractures With Disruption of Pelvic Ring, Fragility Fracture, Internal Fixation","enrollment":48},{"nctId":"NCT02285439","phase":"PHASE1, PHASE2","title":"Study of MEK162 for Children With Low-Grade Gliomas","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2016-05-04","conditions":"Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms","enrollment":105},{"nctId":"NCT05177068","phase":"PHASE2","title":"Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2022-05-13","conditions":"Gastric Cancer","enrollment":42},{"nctId":"NCT07194005","phase":"PHASE2","title":"Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-04","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT06479135","phase":"PHASE3","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","status":"RECRUITING","sponsor":"Kartos Therapeutics, Inc.","startDate":"2024-06-03","conditions":"Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis","enrollment":600},{"nctId":"NCT03217266","phase":"PHASE1","title":"Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma","enrollment":39},{"nctId":"NCT03413384","phase":"PHASE2","title":"To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BrainX Corporation","startDate":"2019-02-15","conditions":"Parkinson's Disease Dementia","enrollment":100},{"nctId":"NCT06874959","phase":"NA","title":"Evaluation of the Pain Relief Effect of Battlefield Acupuncture on Patients With Chronic Low Back Pain Due to Lumbar Spine Degeneration.","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2025-03-15","conditions":"Spondylosis Lumbar","enrollment":60},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT07169240","phase":"PHASE1","title":"Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"ScinnoHub Pharmaceutical Co., Ltd.","startDate":"2023-02-06","conditions":"Healthy Subjects (HS)","enrollment":84},{"nctId":"NCT04385290","phase":"PHASE1, PHASE2","title":"Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT07161323","phase":"NA","title":"SNAG and SNME in Non-Specific Sciatic Pain","status":"RECRUITING","sponsor":"Istinye University","startDate":"2025-07-01","conditions":"Sciatica Pain, Sciatica Acute, Mulligan Mobilization","enrollment":30},{"nctId":"NCT07156513","phase":"NA","title":"Persistent Post-Lumbar Surgery Pain Syndrome (PSPS) Type II is a Common Condition Encountered in Pain Units, With Limited Available Therapeutic Options. Epidural Pulsed Radiofrequency (PRF) Administered Via Catheter Has Demonstrated Greater Efficacy Compared to the Transforaminal Approach. This Rand","status":"COMPLETED","sponsor":"Puerta de Hierro University Hospital","startDate":"2021-01-02","conditions":"Persistent Spinal Pain Syndrome Type II, Failed Back Surgery Syndrome, Chronic Low Back Pain","enrollment":131},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07153692","phase":"NA","title":"Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD","status":"RECRUITING","sponsor":"Wang Ping","startDate":"2025-07-17","conditions":"Parkinson's Disease and Parkinsonism, Dysphagia","enrollment":58},{"nctId":"NCT07151209","phase":"PHASE2","title":"Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":20},{"nctId":"NCT05773092","phase":"PHASE2","title":"A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2023-08-01","conditions":"NSCLC","enrollment":30},{"nctId":"NCT07138300","phase":"NA","title":"Combined Effect of Low Level Laser Therapy and Neural Mobilization on Lumber Disc Prolapse","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-01","conditions":"Low Level Laser Therapy","enrollment":40},{"nctId":"NCT03115983","phase":"NA","title":"LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Empirical Spine, Inc.","startDate":"2017-07-17","conditions":"Degenerative Spondylolisthesis, Lumbar Spinal Stenosis","enrollment":299},{"nctId":"NCT03320629","phase":"PHASE2","title":"A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2017-11-01","conditions":"Refractory or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT07097532","phase":"NA","title":"Cutaneous Silent Period-Based Comparison of DRG-PRF and TFESI in Lumbar Radicular Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"ahmet başarı","startDate":"2025-07-08","conditions":"Lumbar Radicular Pain, Spinal, Inhibition","enrollment":54},{"nctId":"NCT07098949","phase":"NA","title":"Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08","conditions":"Gastric Cancer","enrollment":346},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT06234059","phase":"NA","title":"Modulation of Sensory Acuity With Transcranial Magnetic Stimulation (TMS)","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2025-07","conditions":"Speech","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":243,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"S-1 therapy","genericName":"S-1 therapy","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-1 therapy is a chemotherapy medication that works by inhibiting thymidylate synthase, thereby preventing DNA synthesis and cell division. Used for Advanced gastric cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}